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ABSTRACT: 
Gastrointestinal illnesses cause physical, emotional, and social impact on 
patients. Patient Reported Outcome Measures (PROMs) are increasingly 
used in clinical decision-making, clinical research, and approval of new 
therapies. In the last decade, there has been a rapid increase in the number 
of PROMs in gastroenterology and therefore, the choice between which of 
these PROMs to use can be difficult. Not all PROM instruments currently used 
in research and clinical practice in gastroenterology have gone through a 
rigorous development methodology. New drugs and therapies will not have 
access to the market if the PROMs used in their clinical trials are not validated 
according to the guidelines of the international agencies. Therefore, it is 
important to know the required properties of PROMs when choosing or 
evaluating a drug or a clinical intervention. This paper reviews the current 
literature on how to assess the validity and reliability of PROMs. It 
summarizes the required properties into a practical guide for 
gastroenterologists to use in assessing an instrument for use in clinical 
practice or research. 
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INTRODUCTION: 
More than a century ago, the first health outcome measure was proposed by 
Florence Nightingale by classifying patients into relieved, unrelieved and dead 
(1). Other guides such as mortality rates have historically been used to 
measure health outcomes in the population (2). However, the definition of 
health has changed in the past century to include a wider view of outcomes, 
which includes freedom from disease, ability to perform daily activities, 
happiness, social and emotional well being, and quality of life. The World 
Health Organization (WHO) has defined health as “physical, mental, and 
social well-being, and not merely the absence of disease and infirmity” (3). As 
a result numerous measures have been developed in an attempt to quantify 
health. Health outcome measures are tools used to evaluate an individuals’ 
health using different health related parameters. Patient Reported Outcomes 
Measures (PROMs) are instruments that are completed by patients and 
capture one or more aspects of health (4, 5). The use of PROMs formally to 
monitor surgical outcomes in England has been an important development 
(6). Since 2007, the Department of Health has required the routine 
measurement of patient- reported health outcomes for all NHS patients via its 
PROMs programme (5, 6). PROMs are increasingly used in decision-making 
to encourage a patient-centered approach (5, 7). For this reason, PROMs that 
are chosen and used in practice must be valid, reliable, and clinically useful 
measures. 
There are over 100 PROMs applicable to gastroenterological disorders which 
are described in the Gastrointestinal patients reported outcomes (GI-PRO) 
database (4). The classical physician based health outcome measures are 
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now increasingly being replaced by patient-reported outcome measures 
(PROMs), which enable the assessment and monitoring of disease or 
treatment effects from the patients’ own perception, rather than the health 
professionals’ judgments (which does not always reflects patients’ views) (8, 
9).  
A doctor’s ability to interpret and apply PROMs in clinical practice has a great 
potential to contribute to a better understanding of the patients' well-being. 
There is an increasing use of PROMS in both research and clinical work in 
gastroenterology. It is important differentiate between PROMS for functional 
disorders and those for organic disorders. Patient reported outcomes 
measures should be used in identification of the symptomatic profiles, 
diagnosis and treatment of functional disorders such as Post Prandial Distress 
Syndrome, Epigastric Pain Syndrome, Chronic Idiopathic Nausea, Excessive 
Belching, IBS and other functional diseases (10). The lack of objective 
measurable markers of symptoms improvement, such as stool frequency and 
rectal bleeding, means the evaluation of treatment response has to be based 
on the patients’ reporting of symptoms. The Rome III criteria (11, 12) are very 
useful to assess the outcomes of new treatments for functional 
gastrointestinal disorders.  
Nowadays, PROMs are categorized into generic and disease specific (13, 
14). Generic PROMs are applicable to any disease and are useful for 
comparison or economic studies between different conditions. Specific 
PROMs, on the other hand, are specific for one condition. Both types of 
measures generic and specific are now seen as complementary rather than 
conflicting when appraising patient outcomes. Some of the commonly used 
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generic tools are the European Quality of life 5 dimensions (EQ-5D) (15), the 
short form 36 (SF-36) questionnaire (16) and the Cleveland Quality of life (17, 
18), and the short form 12 (SF-12) (19). Examples of the disease specific 
PROMs are the Inflammatory bowel disease questionnaire (IBDQ) (20) and 
the Rating form of IBD patient concerns (21). A good review of PROMs that 
have been used to evaluate the efficacy of therapeutic agents in functional 
dyspepsia trials was done by Ang et al (22). Mouzas and Pallis reported a 
good review of the PROMs used in inflammatory bowel disease (23). The 
patient-reported outcome and quality of life measures database provides a 
comprehensive list of the available PROM questionnaires (24).  
The increasing number of PROMs in the recent years requires 
gastroenterologists to decide which PROM to use and how to assess each 
measure. Several studies have suggested using standards to assess 
properties such as validity, reliability and responsiveness. Examples of these 
standards have been presented by Terwee et al (25), scientific advisory 
committee of the Medical Outcome Trust (26), EMPRO (Evaluating the 
Measurement of Patient-Reported Outcomes) tool (27), Bombardier and 
Tugwell (28), Andresen (29), Steiner (30)Devon et al (31), McDowell and 
Jenkinson (32), the Food and Drug Administration (FDA)(33, 34) and the 
European Medicines Agency (35) guidelines. The FDA guidance in 2006 (33, 
34) describes how to evaluate PROMs used as effectiveness endpoints in 
clinical trials. These publications describe the required criteria for a successful 
PROM and are written mainly for health outcome specialists and 
methodologists who are involved in developing health outcome measures for 
clinical trials or a evaluating new medical technology. None of these 
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publications individually summarizes these standards into one relatively brief 
yet fairly comprehensive practical checklist for doctors to use in their day-to-
day clinical practice. Before using health outcome measures for research or in 
clinical practice, it is essential to ensure they are appropriate to the context, 
perform well and possess the required characteristics. In this article we 
describe how to assess these requirements: the concept of items generation, 
validity, reliability, responsiveness, utility and cross-cultural adaptation; and 
how to evaluate these measures in a way that is easy to follow and applicable 
in clinical practice.   
 
THE QUALITY PROPERTIES OF PROMs: 
There are 5 main components for good quality PROMs: items selection, 
validity, reliability, responsiveness and interpretability. With the increase 
number of multinational and multicultural clinical research, certain criteria 
regarding cultural, educational and social adaptation of the PROMs are 
needed to use the questionnaires in a different language or country.  
1. Items selection: 
Items can be derived from three main sources(13, 36, 37):  
1. Research: reviewing old PROMs is the most commonly used approach 
in finding items. There are several reasons why old measures can be 
used to derive the new PROMs items; it saves a lot of time and effort, 
there are possibly a limited number of questions to ask about a specific 
problem such as abdominal pain, vomiting..etc., and old measures 
have been repeatedly used and tested in many studies and trials.  
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2. Patients: by asking the patients to identify items and domains to be 
included in the scale. Patients can be excellent sources of health 
outcome measure items. Some techniques like focus groups and key 
informant interviews have been used to collect patients' viewpoints in a 
systematic manner (13). This method of item generation has been 
useful in constructing a quality of life measure for example the 
inflammatory bowel disease questionnaire (IBDQ)(20), the Rating form 
of IBD patient concerns (21) and functional dyspepsia (38). 
3. Clinical observations: items are derived by clinicians based on their 
experience.  
However, the FDA statement (33, 34) considers including patients in 
developing PROM questionnaire is the most important source of items. It 
stresses that items generation should include a wide range of patients to 
represent variations in severity and in population characteristics such as age, 
sex, and educational level. It is important to assess the respondents and 
administrator burden when choosing items. Items that cause undue physical, 
emotional, or cognitive strain on patients generally decrease the quality and 
completeness of PROM data. The language in a PROM should be clear and 
not technical. Items should not offend or discriminate against people for 
example when assessing the emotional aspect of quality of life. Therefore, 
items should be tested on small group of patients for a preliminary or a pilot 
testing to make sure that they are understandable and not ambiguous (39). 
This pilot testing can include any number of patients. The FDA guidance 
mention that the number of patients in the pilot testing is not as critical as the 
cognitive interview quality and patients diversity included in the sample. Pilot 
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testing of items is commonly used in developing quality of life questionnaires 
such as the IBDQ and the UK-IBDQ (20, 40).  
Once the pool of items has been created, a number of statistical techniques 
can be used in order to select the most relevant items:  
1. Frequency of endorsement: The frequency of endorsement (also called 
response rate) examines the proportion of people who select the same item 
response. Only items with endorsement rate between 0.2 – 0.8 (or 20% - 
80%) are chosen (13, 41). Items with lower or higher rates are considered 
redundant because they will add little value to the index. Items with high 
response rates more than 80% (i.e. more than 80% of patients chose the 
same answer) are considered for removal because they cannot be used to 
distinguish between patients. If the same answer was chosen by less than 
20% of patients, then it is possibly not related to the condition and can be 
removed.  
2. Item-total correlation: The item-total correlation is the statistical correlation 
of each item with the total PROM score. The accepted range is between 0.2 
to 0.8 (13). A value below 0.2 indicates that the item is not relevant. A value of 
more than 0.8 indicates that the item is redundant and does not add a value to 
the total scale. 
3. Internal consistency: Internal consistency is the statistical correlation or the 
homogeneity between the items in the measure (20, 25). The internal 
consistency is commonly measured by calculating Cronbach α statistic (13, 
36) (42). The acceptable value of Cronbach α is between 0.7 and 0.9 (13, 25). 
Higher values more than 0.9 may indicate an overlap between items. 
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2.Reliability 
Reliability is the consistency between the score of a health outcome measure 
applied in different circumstances. The principle of reliability is that applying 
the PROM in different occasions or by different observers produces similar 
results (13, 43). Statisticians suggest that a reliability of 0.75 should be the 
minimum requirement for a useful health outcome measure (13). Common 
reliability statistics are Intraclass Correlation Co-efficient (ICC) and Pearson 
correlation co-efficient  (r). They are expressed as a numbers between -1 and 
1 with 0 indicating no reliability; 1 is perfect reliability between the two set of 
tests and a negative number indicates that the two sets of tests change 
inversely. 
Common types of reliability testing are  
 Inter-Observer Reliability is used to assess the degree of consistency 
between different observers assessing the same patients.  
 Test-Retest Reliability is used to assess reliability of the PROM when 
applied on two separate occasions.  To estimate test-retest reliability, 
the measure should be administered to the same group of patients on 
two separate occasions between which there has been no overall 
change in the clinical condition of the patients. Typically a period of 14 
days is acceptable (13). 
3.Responsiveness: 
Responsiveness is the ability of the PROM tool to detect a change in patients’ 
clinical condition. This is estimated by applying the health outcome measure 
to a group of patients whose clinical condition has changed (13, 44). There 
are several statistics for responsiveness but the commonest is the 
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responsiveness ratio, which is calculated by dividing the mean change in 
scores for patients who reported a change by the standard deviation of the 
scores of stable patients (13, 44). Other responsiveness indicators mentioned 
in literature are effect size (ES) (45) and standardized response mean (SRM) 
(46). The acceptable value for responsiveness ratio is 0.5 or 50% (47) (44, 
48). 
4. Validity: 
Validity is the ability of the test to measure what is intended to measure. 
Validity can be broadly divided into three types (referred to as the 3 Cs) (13): 
content validity, construct validity and criterion validity.  
Content validity: checks if the measure as a whole covers all the relevant and 
important aspects of the disease. Experts in the field usually judge content 
validity to ensure items appropriately measures the desired health outcome.  
Construct validity: is used when there is no “gold“ standard measure with 
which a new PROM can be compared (13). A combination of laboratory tests, 
other health outcome measures, or clinical observations might be necessary 
to provide the data that support the construct validation of the PROM (25, 49). 
The common statistic to assess construct validity is by calculating a 
correlation coefficient. An appropriate correlation coefficient for construct 
validity should be somewhere between 0.4 and 0.8 (13, 47).  
Criterion validity: measures the correlation of the new measure with a “ gold 
standard” measure, which exhibit the same characteristics. When the 
correlation is explored at the same time then it is described as “concurrent 
validation”. This is often used when an existing measure is potentially to be 
replaced by a shorter, cheaper or less invasive measure (13). In this case, we 
 11 
would expect a very high correlation co-efficient (≥0.8). When the new 
measure is compared with a criterion that is measured later, this type of 
validation is called “predictive validation”. This type of validation is often used 
with measures that predict future events like response to treatment or 
mortality.  
5. Interpretability  
Interpretability means assigning qualitative meaning to the health outcome 
measure scores (25, 50-52). To aid using PROM in clinical practice, doctors 
should be able to translate the PROM score to clinical meaning by knowing 
the minimal important change ( MIC). The minimal important change  (MIC) is 
defined as ‘‘the smallest difference in score in the domain of interest which 
patients perceive as beneficial and would mandate, in the absence of 
troublesome side effects and excessive cost, a change in the patient’s 
management’’ (53). Another useful information is the “Floor and Ceiling 
Effects”. The ceiling effect is a term used to describe the effect when the 
majority of the patient scores are close to or at the top of the measure. The 
floor effect is a term used when the majority of patient scores are close to or 
at the bottom of the measure (25). A measure is said to have a floor or ceiling 
effect when more than 15% of patients score the lowest or highest possible 
score, respectively (25). If floor or ceiling effects are present, it is difficult to 
accurately assess the health outcomes of patients who score at the extreme 
ends of the PROM. Results from those groups of patients should be 
interpreted with caution.  
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6. Cross-cultural adaptation 
Cross-cultural adaptation is the process that deals with language and cultural 
adaptation issues when preparing the PROMs for use in another country (54, 
55). Items should not only be translated linguistically, but also must adapt 
culturally to the target country culture. For example a questions about difficulty 
in using fork in eating may not be applicable in a country where fork is not 
used in eating. The cross cultural adaptation involves forward and backward 
translation of the questions or items, review the results by linguistics, 
methodologists, statisticians and health care professionals and pretesting the 
PROM in the small group of patients to check the clarity of the PROM in the 
new setting and its consistency with the original PROM version (54). The final 
step involves psychometric validation of the new PROM in the target 
population to check validity, reliability, and responsiveness (13, 55). In some 
ethnic minorities or special group of patients, there is a need for specific 
cultural and language educational materials such as the use of pictogram, 
smileys or other picture based representations (56, 57). A good example of a 
picture based PROM is the Gastro-oesophageal reflux disease analyzer 
(GERDyzer) questionnaire which compromises 10 dimensions each is 
illustrated by pictograms drawings (58). In fact a recent study published by 
Tack et al showed that the use of pictograms with verbal descriptors 
significantly improve the reliability of PWOMs by around 30% by avoiding 
potential bias by patients (59).  
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CHECKLIST TO EVALUATE PROMs:  
The five important aspects when evaluating the PROMS: Items generation, 
reliability, validity, responsiveness and interpretability. Each aspect includes 
one or more psychometric testing. Cross-cultural adaptation is only needed 
when using the PROM in another language or country. We have produced a 
simple checklist (Table 1) to evaluate the PROMs without using excessive 
statistical technical terms.  
 
CONCLUSIONS:  
This paper intends to provide a practical overview of the main components for 
a good quality PROM; it does not intend to provide a detailed description of 
each component. Readers who require more detailed explanations are 
encouraged to refer the references cited in the paper. The Food and Drug 
Administration (FDA)(33) and the European Medicines Agency (35) guidelines 
provide further recommendations on the proper development and validation of 
PROMs especially for clinical trials.  
A good example of a well-validated PROM is the inflammatory bowel disease 
questionnaire (IBDQ). IBDQ was developed in 1985 as a quantitative, disease 
specific HRQoL measure in patients with inflammatory bowel disease. A 
number of patients with IBD and health professionals were asked to list all 
problems they had observed or experienced as a direct result of IBD. This 
process resulted in a total of 150 items. All these items were then 
administered to another group of patients with IBD to rate each problem on a 
5-point Likert scale, ranging from a low score (score 1) indicating no problem 
to a high score (score 5) indicating a severe problem. A final list of 32 was 
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derived and reviewed by experienced clinicians, the items were grouped into 
four groups: Gastrointestinal symptoms, systemic symptoms, emotional 
dysfunction and social dysfunction (60). The final version of IBDQ had good 
reproducibility (ICC was 0.7) and responsiveness (by calculating the 
responsiveness ration on patients who reported change in a 7-point 
assessment of their condition). The IBDQ had good construct validity when 
correlated with disease specific and generic PROMs (61) (62-65). The 
clinically important change in score was observed to be a decrease of 
between 16 and 30 points (66). IBDQ was validated into different languages 
versions and have further proved its validity, internal consistency and 
reliability in several validation studies worldwide (64, 65, 67-77).   
Because new therapies in gastroenterology are rapidly emerging. PROMs are 
increasingly used in clinical decision-making. There is a need to support and 
educate gastroenterologist on how to assess these tools to encourage them 
to use them in clinical practice.  
Every PROM  tool should have five important properties: Items should come 
from a reliable source and should be clear to patients, the PROM must yield 
consistent measurements, i.e. must be reliable, and the PROM instrument 
must measure the variable it is said to measure, i.e. must be valid,  should 
change with the change in patients’ condition “ responsive” and can be easily 
transferred to clinical meaningful values “interpretability”.  
 
Conflict of interest: None  
Authors' contributions: LA contributed in writing the manuscript, reviewing 
the literature. HAH and JGW contributed in reviewing the literature and 
 15 
examining the content of the manuscript. All authors approved the final 
version of the manuscript 
 16 
 
 
 
Table 1: Checklist for evaluating the PROM questionnaires:  
1. Items Generation: Were items assessed for? 
 Clarity and lack of ambiguity 
 Frequency of endorsement (desired value 20-80%) 
 Internal consistency (desired Cronbach Alpha 0.7-0.9) 
 Item total correlation (desired value 0.2-0.8) 
2. Reliability:  
 Was the PROM checked for test-retest reliability 
 Was the PROM checked for inter-observer reliability 
 Was the reliability coefficient acceptable (more than 0.75) 
3. Responsiveness: 
 Was the PROM assessed for responsiveness using an appropriate 
measure ( such as responsiveness ratio, effect size, or 
standardized response mean (SRM)) 
 Was the value acceptable ( e.g responsiveness ratio more than 
0.5) 
4. Validity: 
 Was the validity of the PROM assessed using the appropriate 
method ( construct validity and/or criterion validity) 
 Was the correlation coefficient >= the required value of 0.4 for 
construct validity and 0.8 for criterion validity  
5. Interpretability: 
 Can the PROM results be interpreted easily for clinical practice ? 
 Were the values for MIC, SEM, SDC and floor and ceiling effects 
reported properly? 
6. Cross cultural adaptation (only if the PROM is used in a different 
language/culture): 
 Did the PROM go through a proper cross cultural validation 
process? 
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